NCT02755870View on ClinicalTrials.gov

A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Healthy Volunteers - Male and Female
Interventions
OTHER

CNM-Au8

Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a new nanocatalytic drug class

OTHER

Placebo

Placebo oral suspension which matches the volume of the experimental nanocrystal suspension

Trial Locations (1)

2333 CL

Centre for Human Drug Research (CHDR), Leiden

Sponsors

Lead Sponsor

Clene Nanomedicine
All Listed Sponsors
lead

Clene Nanomedicine

INDUSTRY

NCT02755870 - A Phase I SAD and MAD Clinical Trial of CNM-Au8 in Healthy Male and Female Volunteers | Biotech Hunter | Biotech Hunter